Developmental Toxicology

Total Page:16

File Type:pdf, Size:1020Kb

Developmental Toxicology Toxicology VOL. VOL. 27 about the book… 27 TARGET ORGAN Highlighting latest advances in genetics and biochemistry, the completely revised Third TOXICOLOGY Edition reviews the field from basic science, clinical, epidemiological, and regulatory SERIES TARGET ORGAN TOXICOLOGY SERIES perspectives. Contributions from top opinion leaders in the field bring together developments in molecular embryology and cell biology as they apply to problems Series Editors in developmental toxicology. It covers testing of pharmaceutical and environmental agents and interpretation of developmental toxicology data, highlighting mathematical A. Wallace Hayes • John A. Thomas • Donald E. Gardner and statistical techniques, as well as the effects of toxic exposure on the functional D development of various organs. EVELOPMENTAL The relationship between maternal and developmental toxicology is examined, in addition to current techniques for studying chemical disposition, metabolism, and placental transfer. Close attention is given to the regulatory aspects of testing and risk assessment. Pre- and postconceptional clinical care and genetic factors in clinical developmental toxicology are also discussed. Key topics include: • the roles of apoptosis and signal transduction pathways T in normal and abnormal development HIRD • the role of epigenetic changes in development • the role of nutrition and individual susceptibility • the utility of bioinformatics E • global and targeted gene expression changes DION DEVELOPMENTAL about the editors... T T DEBORAH K. HANSEN is a research biologist in the Division of Genetic and Reproductive I Toxicology, the National Center for Toxicological Research, Jefferson and Adjunct OXICOLOGY TOXICOLOGY Associate Professor of Pharmacology and Interdisciplinary Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. She received her M.S. in genetics from Iowa State University, Ames, Iowa and her Ph.D. in medical genetics from Indiana University School of Medicine, Indianapolis, Indiana, USA. Dr. Hansen is a THIRD EDIONT I member of both the Teratology Society, of which she is Secretary, and the Society of Toxicology. She has contributed to numerous peer-reviewed publications on the subjects of reproductive toxicology, embryotoxicity, and developmental toxicology. BARBARA D. ABBOTT is Research Biologist in the Reproductive Toxicology Division of the U.S. Environmental Protection Agency (EPA), Research Triangle Park, North Carolina, USA. She received both her M.S. and Ph.D. in toxicology from North Carolina State University, Raleigh, North Carolina, USA. Dr. Abbott is a member of the Teratology Society and the Society of Toxicology. She is Associate Editor of Toxicological Sciences and serves on the editorial board of Reproductive Toxicology. Dr. Abbott has also received several Scientific and Technological Achievement awards from the U.S. EPA and has Edited by been a frequent invited lecturer at international meetings and symposiums. Her main Hansen area of interest is developmental toxicity, particularly complex, interactive signal Deborah K. Hansen transduction and receptor-mediated pathways. 54376 Abbott Printed in the United States of America Barbara D. Abbott DEVELOPMENTAL TOXICOLOGY TARGET ORGAN TOXICOLOGY SERIES Series Editors A. Wallace Hayes, John A. Thomas, and Donald E. Gardner Developmental Toxicology, Third Edition. Deborah K. Hansen and Barbara D. Abbott, editors, 408 pp., 2008 Adrenal Toxicology. Philip W. Harvey, David J. Everett, and Christopher J. Springall, editors, 336 pp., 2008 Cardiovascular Toxicology, Fourth Edition. Daniel Acosta, Jr., editor, 712 pp., 2008 Toxicology of the Gastrointestinal Tract. Shayne C. Gad, editor, 384 pp., 2007 Immunotoxicology and Immunopharmacology, Third Edition. Robert Luebke, Robert House, and Ian Kimber, editors, 676 pp., 2007 Toxicology of the Lung, Fourth Edition. Donald E. Gardner, editor, 696 pp., 2006 Toxicology of the Pancreas. Parviz M. Pour, editor, 720 pp., 2005 Toxicology of the Kidney, Third Edition. Joan B. Tarloff and Lawrence H. Lash, editors, 1200 pp., 2004 Ovarian Toxicology. Patricia B. Hoyer, editor, 248 pp., 2004 Cardiovascular Toxicology, Third Edition. Daniel Acosta, Jr., editor, 616 pp., 2001 Nutritional Toxicology, Second Edition. Frank N. Kotsonis and Maureen A. Mackey, editors, 480 pp., 2001 Toxicology of Skin. Howard I. Maibach, editor, 558 pp., 2000 Neurotoxicology, Second Edition. Hugh A. Tilson and G. Jean Harry, editors, 386 pp., 1999 Toxicant–Receptor Interactions: Modulation of Signal Transductions and Gene Expression. Michael S. Denison and William G. Helferich, editors, 256 pp., 1998 Toxicology of the Liver, Second Edition. Gabriel L. Plaa and William R. Hewitt, editors, 444 pp., 1997 Free Radical Toxicology. Kendall B. Wallace, editor, 454 pp., 1997 Endocrine Toxicology, Second Edition. Raphael J. Witorsch, editor, 336 pp., 1995 Carcinogenesis. Michael P. Waalkes and Jerrold M. Ward, editors, 496 pp., 1994 Developmental Toxicology, Second Edition. Carole A. Kimmel and Judy Buelke-Sam, editors, 496 pp., 1994 Nutritional Toxicology. Frank N. Kotsonis, Maureen A. Mackey, and Jerry J. Hjelle, editors, 336 pp., 1994 Ophthalmic Toxicology. George C. Y. Chiou, editor, 352 pp., 1992 Toxicology of the Blood and Bone Marrow. Richard D. Irons, editor, 192 pp., 1985 Toxicology of the Eye, Ear, and Other Special Senses. A. Wallace Hayes, editor, 264 pp., 1985 Cutaneous Toxicity. Victor A. Drill and Paul Lazar, editors, 288 pp., 1984 DEVELOPMENTAL TOXICOLOGY THIRD EDI T ION Edited by Deborah K. Hansen National Center for Toxicological Research Jefferson, Arkansas, USA Barbara D. Abbott U.S. Environmental Protection Agency Research Triangle Park, North Carolina, USA Informa Healthcare USA, Inc. 52 Vanderbilt Avenue New York, NY 10017 C 2009 by Informa Healthcare USA, Inc. Informa Healthcare is an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10987654321 International Standard Book Number-10: 1-4200-5437-6 (Hardcover) International Standard Book Number-13: 978-1-4200-5437-8 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the conse- quence of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organiza- tion that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Developmental toxicology. – 3rd ed. / edited by Deborah K. Hansen, Barbara D. Abbott. p. ; cm. – (Target organ toxicology series ; 27) Includes bibliographical references and index. ISBN-13: 978-1-4200-5437-8 (hardcover : alk. paper) ISBN-10: 1-4200-5437-6 (hardcover : alk. paper) 1. Developmental toxicology. 2. Fetus–Effect of drugs on. 3. Teratogenic agents. I. Hansen, Deborah Kay, 1952– II. Abbott, Barbara D. III. Series. [DNLM: 1. Abnormalities, Drug-Induced. 2. Embryonic Development–drug effects. 3. Fetal Development–drug effects. 4. Risk Assessment. 5. Teratogens. QS 679 D4893 2008] RA1224.45.D47 2008 618.32–dc22 2008026172 For Corporate Sales and Reprint Permissions call 212-520-2700 or write to: Sales Department, 52 Vanderbilt Avenue, 7th floor, New York, NY 10017. Visit the Informa Web site at www.informa.com and the Informa Healthcare Web site at www.informahealthcare.com Preface This Third Edition of Developmental Toxicology comes 14 years after the publi- cation of the Second Edition. Much has happened in the field of developmental toxicology over that period of time. Many of the advances have been in the areas of mechanistic examinations of developmental toxicants as well as in risk assess- ment, so these are the two general areas that we have chosen to focus on in this volume. The first two editions serve as a strong foundation on which to build. Many basic issues in the field of developmental toxicology were covered in those edi- tions, and the information provided in them still remains relevant today. How- ever, significant strides have been made in the area of mechanistic information. Potential mechanisms of developmental toxicants that are covered in this edition include apoptosis, alterations in signal transduction pathways, as well as effects on nutrition and epistasis. The role of the placenta in the transfer of developmental toxicants, nutrients, and wastes, as well as its role in metabolism of compounds is also covered. New techniques being used to address mechanistic
Recommended publications
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • WO 2012/170711 Al 13 December 2012 (13.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/170711 Al 13 December 2012 (13.12.2012) P O P C T (51) International Patent Classification: (72) Inventors; and G01N33/5 74 (2006.01) (75) Inventors/Applicants (for US only): PAWLOWSKI, Traci [US/US]; 2014 N Milkweed Loop, Phoenix, AZ (21) International Application Number: 85037 (US). YEATTS, Kimberly [US/US]; 109 E. Pierce PCT/US2012/041387 Street, Tempe, AZ 85281 (US). AKHAVAN, Ray (22) International Filing Date: [US/US]; 5804 Malvern Hill Ct, Haymarket, VA 201 69 7 June 2012 (07.06.2012) (US). (25) Filing Language: English (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N. MacArthur Blvd., Irving, TX 75039 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 61/494,196 7 June 201 1 (07.06.201 1) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 61/494,355 7 June 201 1 (07.06.201 1) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 61/507,989 14 July 201 1 (14.07.201 1) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicant (for all designated States except US): CARIS HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, LIFE SCIENCES LUXEMBOURG HOLDINGS, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, S.A.R.L [LU/LU]; Rue De Maraichers, L2124 Luxem MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, bourg, Grand-Duche De Luxembourg (LU).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0228233 A1 Pawlowski Et Al
    US 20140228233A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0228233 A1 Pawlowski et al. (43) Pub. Date: Aug. 14, 2014 (54) CIRCULATING BOMARKERS FOR CANCER Publication Classification (76) Inventors: Traci Pawlowski, Laguna Hills, CA (51) Int. Cl. (US); Kimberly Yeatts, Tempe, AZ GOIN33/574 (2006.01) (US); Ray Akhavan, Haymarket, VA CI2O I/68 (2006.01) (US) (52) U.S. Cl. CPC ........ G0IN33/57434 (2013.01): CI2O I/6886 (21) Appl. No.: 14/124.548 (2013.01) USPC .............................. 506/9; 435/7.92; 435/723 (22) PCT Fled: Jun. 7, 2012 (57) ABSTRACT (86) PCT NO.: PCT/US 12/41387 Biomarkers can be assessed for diagnostic, therapy-related or S371 (c)(1), prognostic methods to identify phenotypes, such as a condi (2), (4) Date: Mar. 24, 2014 tion or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, dis ease stages, and stages of a condition, and to determine treat Related U.S. Application Data ment efficacy. Circulating biomarkers from a bodily fluid can (60) Provisional application No. 61/494,196, filed on Jun. be used in profiling of physiological states or determining 7, 2011, provisional application No. 61/494,355, filed phenotypes. These include nucleic acids, protein, and circu on Jun. 7, 2011, provisional application No. 61/507, lating structures Such as vesicles, and nucleic acid-protein 989, filed on Jul. 14, 2011. complexes. Patent Application Publication US 2014/0228233 A1 ?oueoseuon]-, ?oueoseuon]-, ?oueoseuon]-, Patent Application Publication Aug. 14, 2014 Sheet 3 of 22 US 2014/0228233 A1 ?oueoseuon]-, ?oueoseuon]-, ?oueoseuon]-, Patent Application Publication Aug.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Cross-Tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients with Advanced Tumors Induced by Causal Alterations of ALK And/Or MET ("CREATE")
    EORTC Avenue E. Mounierlaan 83/11 Brussel 1200 Bruxelles België – Belgique Tel: +32 2 774 16 11 e-mail: [email protected] www.eortc.org EORTC Network of Core Institutions (NOCI) Cross-tumoral phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE") EORTC protocol 90101 (EudraCT number 2011-001988-52) (NCT01524926) Study Coordinator: Patrick Schöffski Protocol Date of PRC Amendment reference version approval/notification N° Classification Outline December 03, 2010 ---- ---- 1.0 July 27, 2011 ---- ---- 2.0 February 08, 2012 1 Scientific 3.0 May 15, 2012 2 Scientific 4.0 March 28, 2014 3 Scientific 5.0 June 04, 2014 4 Scientific 6.0 March 26, 2015 5 Scientific 7.0 April 21, 2015 6 Scientific 8.0 August 17, 2015 7 Scientific 9.0 February 25, 2016 8 Scientific 9.1 April 13, 2016 9 Administrative 10.0 February 06, 2017 10 Scientific Version 10.0 / February 06, 2017 Copyright EORTC 2017 EORTC-90101 CREATE Contact addresses Writing Committee: P. Schöffski, University Hospitals Leuven, Leuven, Belgium EORTC Headquarters team, Brussels, Belgium Study Coordinator: Patrick Schöffski Phone: +32 16 346900 E-mail: [email protected] Clinical Research Sandrine Marreaud Physician: Phone: +32 2 774 16 85 E-mail: [email protected] Clinical Scientist: Angélique Deleersnijder Phone: +32 2 774 10 35 E-mail: [email protected] Project Manager: Dominiek Staelens Phone: +32 2 774 15 34 E-mail: [email protected] Data Manager: Tiana
    [Show full text]
  • CUSTOMS TARIFF - SCHEDULE 99 - I
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2016 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
    Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Related Titles Smith, D. A., Allerton, C., Kalgutkar, A. S., Curry, S. H., Whelpton, R. van de Waterbeemd, H., Walker, D. K. Drug Disposition and Pharmacokinetics and Metabolism Pharmacokinetics in Drug Design From Principles to Applications 2012 2011 ISBN: 978-3-527-32954-0 ISBN: 978-0-470-68446-7 Gad, S. C. (ed.) Rankovic, Z., Morphy, R. Development of Therapeutic Lead Generation Approaches Agents Handbook in Drug Discovery 2012 2010 ISBN: 978-0-471-21385-7 ISBN: 978-0-470-25761-6 Tsaioun, K., Kates, S. A. (eds.) Han, C., Davis, C. B., Wang, B. (eds.) ADMET for Medicinal Chemists Evaluation of Drug Candidates A Practical Guide for Preclinical Development 2011 Pharmacokinetics, Metabolism, ISBN: 978-0-470-48407-4 Pharmaceutics, and Toxicology 2010 ISBN: 978-0-470-04491-9 Sotriffer, C. (ed.) Virtual Screening Principles, Challenges, and Practical Faller, B., Urban, L. (eds.) Guidelines Hit and Lead Profiling 2011 Identification and Optimization ISBN: 978-3-527-32636-5 of Drug-like Molecules 2009 ISBN: 978-3-527-32331-9 Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Pharmacokinetic Properties of Functional Groups and Organic Compounds The Author All books published by Wiley-VCH are carefully produced. Nevertheless, authors, Dr. Florencio Zaragoza D¨orwald editors, and publisher do not warrant the Lonza AG information contained in these books, Rottenstrasse 6 including this book, to be free of errors. 3930 Visp Readers are advised to keep in mind that Switzerland statements, data, illustrations, procedural details or other items may inadvertently be Cover illustration: inaccurate.
    [Show full text]
  • Further Observations to Elucidate the Role of Interventricular Dispersion
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector JACC Vol. 30, No. 6 1575 November 15, 1997:1575–84 Further Observations to Elucidate the Role of Interventricular Dispersion of Repolarization and Early Afterdepolarizations in the Genesis of Acquired Torsade de Pointes Arrhythmias A Comparison Between Almokalant and d-Sotalol Using the Dog as Its Own Control S. CORA VERDUYN, PHD, MARC A. VOS, PHD, JOLANDA VAN DER ZANDE, BS, ATILLA KULCSA` R, PHD, HEIN J. J. WELLENS, MD, FACC Maastricht, The Netherlands Objectives. We sought to further elucidate the role of early 60 ms; d-sotalol: 80 6 45 ms, p < 0.05). The incidence of EADs (18 afterdepolarizations (EADs) and interventricular dispersion of of 22 vs. 11 of 24, p < 0.05) and single ectopic beats (EBs) (1.5 6 repolarization (DAPD) in the genesis of acquired torsade de 2 vs. 24 6 32, p < 0.01) was more frequently observed after pointes (TdP) arrhythmias. almokalant than after d-sotalol. Moreover, multiple EBs only Background. Administration of class III agents can be associ- occurred after almokalant. These beats interfered with the basic ated with TdP. We developed a dog model in which TdP can be rhythm, leading to dynamic changes in left ventricular APD and to reproducibly induced by pacing after d-sotalol. This model shows additional increases in DAPD. Spontaneous TdP was observed in reproducible results over weeks. 9 of 14 dogs after almokalant and could be increased to 12 of 14 Methods. In 14 anesthetized dogs with chronic complete atrio- with programmed electrical stimulation.
    [Show full text]